📊 SCNX Key Takeaways
Is Scienture Holdings, Inc. (SCNX) a Good Investment?
Scienture Holdings is an early-stage pharmaceutical company with fundamentally unsustainable economics, burning $13.4M annually in operating cash while generating only $431.6K in revenue. With $6.7M in cash reserves, the company faces critical runway exhaustion within six months at current burn rates, necessitating dilutive financing. While gross margins are healthy at 76.8%, the company is losing $99 for every $1 of revenue, indicating severe pre-commercialization stage distress.
Why Buy Scienture Holdings, Inc. Stock? SCNX Key Strengths
- Revenue growth of 215.9% year-over-year demonstrates emerging market traction
- Gross margin of 76.8% suggests viable product economics if company reaches scale
- Conservative balance sheet with low leverage (0.03x Debt/Equity) and strong liquidity ratios (2.89x current ratio)
SCNX Stock Risks: Scienture Holdings, Inc. Investment Risks
- Operating cash burn of $13.4M annually against $6.7M cash position creates existential runway crisis
- Operating loss of $42.6M against minimal $431.6K revenue indicates company losing ~$99 per $1 of revenue
- Pre-commercial stage pharmaceutical company with no evidence of approved products or near-term revenue inflection
Key Metrics to Watch
- Monthly cash burn rate and path to operating cash flow breakeven
- Revenue growth acceleration and customer acquisition pipeline
- Regulatory approval status and clinical trial milestones
Scienture Holdings, Inc. (SCNX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.89x current ratio provides a solid financial cushion.
SCNX Profit Margin, ROE & Profitability Analysis
SCNX vs Healthcare Sector: How Scienture Holdings, Inc. Compares
How Scienture Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Scienture Holdings, Inc. Stock Overvalued? SCNX Valuation Analysis 2026
Based on fundamental analysis, Scienture Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Scienture Holdings, Inc. Balance Sheet: SCNX Debt, Cash & Liquidity
SCNX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Scienture Holdings, Inc.'s revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $2.48 reflects profitable operations.
SCNX Revenue Growth, EPS Growth & YoY Performance
SCNX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $64.9K | -$1.8M | $-0.19 |
| Q2 2025 | $10.3K | -$1.8M | $-0.48 |
| Q1 2025 | $10.3K | -$3.1M | $-0.33 |
| Q3 2024 | $64.9K | -$678.0K | $-1.34 |
| Q2 2024 | $18.7K | -$678.0K | $-1.30 |
| Q1 2024 | $493.3K | -$678.0K | $-1.01 |
| Q3 2023 | $2.1M | -$503.0K | $-0.91 |
| Q2 2023 | $2.3M | -$678.0K | $-1.99 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Scienture Holdings, Inc. Dividends, Buybacks & Capital Allocation
SCNX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Scienture Holdings, Inc. (CIK: 0001382574)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SCNX
What is the AI rating for SCNX?
Scienture Holdings, Inc. (SCNX) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SCNX's key strengths?
Claude: Revenue growth of 215.9% year-over-year demonstrates emerging market traction. Gross margin of 76.8% suggests viable product economics if company reaches scale.
What are the risks of investing in SCNX?
Claude: Operating cash burn of $13.4M annually against $6.7M cash position creates existential runway crisis. Operating loss of $42.6M against minimal $431.6K revenue indicates company losing ~$99 per $1 of revenue.
What is SCNX's revenue and growth?
Scienture Holdings, Inc. reported revenue of $431.6K.
Does SCNX pay dividends?
Scienture Holdings, Inc. pays dividends, with $14.9M distributed to shareholders in the trailing twelve months.
Where can I find SCNX SEC filings?
Official SEC filings for Scienture Holdings, Inc. (CIK: 0001382574) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SCNX's EPS?
Scienture Holdings, Inc. has a diluted EPS of $-2.70.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SCNX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Scienture Holdings, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SCNX stock overvalued or undervalued?
Valuation metrics for SCNX: ROE of -59.2% (sector avg: 15%), net margin of -9,618.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SCNX stock in 2026?
Our dual AI analysis gives Scienture Holdings, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SCNX's free cash flow?
Scienture Holdings, Inc.'s operating cash flow is $-13.4M, with capital expenditures of $12.0K. FCF margin is -3,102.7%.
How does SCNX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9,618.0% (avg: 12%), ROE -59.2% (avg: 15%), current ratio 2.89 (avg: 2).